Comparative Pharmacology
Head-to-head clinical analysis: INSULIN versus MERILOG SOLOSTAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INSULIN versus MERILOG SOLOSTAR.
Insulin vs MERILOG SOLOSTAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lowers blood glucose by binding to insulin receptors on target cells, activating tyrosine kinase activity, promoting glucose uptake via GLUT4 translocation, stimulating glycogen synthesis, and inhibiting gluconeogenesis and lipolysis.
Insulin glargine is a recombinant human insulin analog that exhibits prolonged duration of action due to slow subcutaneous absorption. It binds to insulin receptors, activating downstream signaling pathways involved in glucose uptake, glycogen synthesis, and lipogenesis.
Individualized based on weight, insulin sensitivity, and metabolic needs. Type 1 diabetes: total daily dose (TDD) 0.3–1.5 units/kg/day, typically 50% basal (long-acting) and 50% prandial (rapid/short-acting). Type 2 diabetes: starting dose 0.1–0.2 units/kg/day or 10 units basal once daily, titrated based on fasting glucose. Intensive regimens use basal-bolus approach.
0.5 mg subcutaneously once a day.
None Documented
None Documented
Terminal elimination half-life: 5-6 minutes for regular insulin; biphasic with initial rapid phase (4-5 min) and slower phase. Clinical context: short half-life necessitates continuous infusion or multiple daily injections.
Terminal half-life is about 24 hours (range 18–30 hours), allowing once-daily dosing.
Renal: ~60-80% (degraded in kidney); hepatic: ~20-40% (degraded in liver); only a small fraction (<1%) excreted unchanged in urine.
Approximately 80% of the dose is excreted renally as unchanged drug, with 20% eliminated via bile/feces.
Category A/B
Category C
Insulin
Insulin